Immune System Key Ltd   Report issue

For profit Phase 2
Founded: Jerusalem Israel (2005)

Organization Overview

First Clinical Trial
2013
NCT01690741
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Immune System Key Ltd

Active Ingredients

Drugs in Phase 2 Trials (2)

doxorubicin (Doxil) (2 trials)

nerofe (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Neoplasms (Phase 1)

Ovarian Neoplasms (Phase 2)

Preleukemia (Phase 2)

Triple Negative Breast Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 2